Summary
The has been updated to strengthen the warning to avoid prescribing in pregnancy. The change was made after a study showed an increased risk of major congenital malformations associated with the medicine.
Pregabalin is an antiepileptic medicine used for the treatment of neuropathic pain and as an adjunctive therapy for partial seizures.
Women should use effective contraception if they are taking pregabalin and treatment should not be prescribed to pregnant women unless the benefits to the mother clearly outweigh the potential risks to their unborn child.
What’s new in this article
The strengthened warning follows recent data from a Nordic observational study of more than 2,700 pregnant women exposed to pregabalin in the first trimester. The study used data from national registries in Denmark, Finland, Norway and Sweden and compared babies born to mothers who took pregabalin, lamotrigine, duloxetine or none of these medicines. The study found a higher prevalence of major congenital malformations among babies exposed to pregabalin in utero compared to babies who were not exposed (5.9% vs. 4.1%).[1]
In response to these findings, the pregnancy category for pregabalin has been changed from B3 to D in Australia. The PI for the innovator pregabalin product, Lyrica, has been updated to include additional warnings and a summary of the results from the Nordic study. Generic sponsors of pregabalin will update their PIs to align with this safety information.
What should health professionals do
Health professionals should inform women using pregabalin about the potential risks to an unborn baby and advise them to use effective contraception during treatment.
Pregabalin should only be prescribed during pregnancy if the benefit to the patient clearly outweighs the potential risk to the fetus – the patient should understand the benefits and risks of pregabalin and be aware of alternatives, and be part of the decision-making process.
Background
Previously, the Therapeutic Goods Administration (TGA) evaluated the safety of epilepsy medicines during pregnancy following a review in the UK.[2] As a result, the TGA updated precautions for the use of phenytoin, phenobarbital, primidone and zonisamide in pregnancy.[3]
At that time, no firm conclusions could be drawn on the possible teratogenic effects of pregabalin in the UK study and the TGA’s Advisory Committee on Medicines found the PI for pregabalin adequately described the risks in pregnancy and did not need updating.[4]
PI changes for Lyrica
The pregnancy category for pregabalin has been changed from B3 to D.
Section 4.4 now includes a special warning for women of childbearing age which states:
‘Lyrica use in the first trimester of pregnancy may cause major birth defects in the unborn child. Pregabalin should not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the fetus. Women of childbearing potential have to use effective contraception during treatment.’
Section 4.6 now includes a summary of the Nordic observational study:
‘Data from a Nordic observational study of more than 2,700 pregnancies exposed to pregabalin in the first trimester showed a higher prevalence of major congenital malformations (MCM) among the paediatric population (live or stillborn) exposed to pregabalin compared to the unexposed population (5.9% vs. 4.1%).
‘The risk of MCM among the paediatric population exposed to pregabalin in the first trimester was slightly higher compared to unexposed population (adjusted prevalence ratio and 95% confidence interval: 1.14 (0.96-1.35)), and compared to population exposed to lamotrigine (1.29 (1.01-1.65)) or to duloxetine (1.39 (1.07-1.82)).
‘The analyses on specific malformations showed higher risks for malformations of the nervous system, the eye, orofacial clefts, urinary malformations and genital malformations, but numbers were small and estimates imprecise.’
Reference
| [1] | Wise J. . BMJ 2022;377:o1010 doi: (Published 21 April 2022). |
|---|---|
| [2] | Medicines and Healthcare products Regulatory Agency. 2021. |
| [3] | . Medicines Safety Update 22 June 2022. |
| [4] | Therapeutic Goods Administration. Advisory Committee on Medicines meeting statement. 2021. |
Disclaimer
Medicines Safety Update is aimed at health professionals. It is intended to provide practical information to health professionals on medicine safety, including emerging safety issues. The information in Medicines Safety Update is necessarily general and is not intended to be a substitute for a health professional’s judgment in each case, taking into account the individual circumstances of their patients. Reasonable care has been taken to ensure that the information is accurate and complete at the time of publication. The Australian Government gives no warranty that the information in this document is accurate or complete, and shall not be liable for any loss whatsoever due to negligence or otherwise arising from the use of or reliance on this document.
© Commonwealth of Australia 2022
This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to .
For the latest safety information from the TGA, via the TGA website.
For correspondence or further information about Medicines Safety Update, contact the TGA’s Pharmacovigilance Branch at .
Medicines Safety Update is written by staff from the Pharmacovigilance Branch.
Editor: Elspeth Kay
Deputy Editor: Fiona Mackinnon
Contributors: Leanne Nelson, Kat Chen
